NBSE 0.00 NeuBase Therapeutics, Inc.
| Range: | 0.36-4.44 | Vol Avg: | 128236 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | 0.95 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri May 28 2004 | Empoloyees: | 37 | ||
| CUSIP: | 64132K102 | CIK: | 0001173281 | ISIN: | US64132K2015 | Country: | US |
| CEO: | Mr. Todd P. Branning | Website: | https://www.neubasetherapeutics.com | ||||
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow